Meda files Acnex MAA in Europe
The company’s MAA includes 29 countries using a decentralised procedure (DCP). Registration in Russia, Turkey and the CIS countries will follow. Meda CEO Anders Lonner said Acnex is
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.